Status:
SUSPENDED
Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early Breast Cancer
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Breast Cancer
Eligibility:
FEMALE
Up to 50 years
Phase:
NA
Brief Summary
For early breast cancer, local surgery followed by breast radiation is a standard local treatment. It has been found that the original primary tumor site, the lumpectomy site, is the commonest locatio...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Women with pathologic stage I to IIB invasive mammary breast cancer.
- Tumor size over 1 cm.
- Patient age 50 years or younger.
- Primary tumor non-lobular.
- Primary tumor non-low grade or Oncotype DX score \> 18.
- Patient is six weeks or earlier post-lumpectomy.
- Seroma is clinically palpable and symptomatic causing discomfort and/or swelling of the lumpectomy site OR re-excision of the lumpectomy site is planned.
Exclusion
Key Trial Info
Start Date :
August 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04339517
Start Date
August 17 2021
End Date
August 30 2026
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Regional Cancer Program; Lawson Research Institute
London, Ontario, Canada, N6A 4L6